who training workshop on pharmaceutical quality, gmp and bioequivalence
DESCRIPTION
János Pogány, pharmacist, PhD consultant to WHO Tanzania, 2 1 August 2006 E-mail: pogany .janos @ chello .hu. WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence. Expression of Interest and Guidelines on Assessment of Applications for Prequalification. Abbreviations. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/1.jpg)
2006.08.21. Pogány - Tanzania 1/36
WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence
János Pogány, pharmacist, PhD consultant to WHO
Tanzania, 21 August 2006E-mail: [email protected]
Expression of Interest andGuidelines on Assessment of
Applications for Prequalification
![Page 2: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/2.jpg)
2006.08.21. Pogány - Tanzania 2/36
AbbreviationsAPI Active Pharmaceutical Ingredient DRA Drug Regulatory Authority EoI Expression of Interest FDC Fixed-Dose CombinationFPP Finished Pharmaceutical ProductGMP Good Manufacturing PracticesICH International Conference on HarmonizationMA Marketing AuthorizationPQ PrequalificationTRSTechnical Report SeriesYellow → emphasis Green → WHO Blue → ICH region
![Page 3: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/3.jpg)
2006.08.21. Pogány - Tanzania 3/36
Objectives of the workshopWHO Prequalification Program is motivated: to involve countries that want to benefit
from the (currently free-of-charge) PQ Program, and
to provide more information to African regulators about the ongoing activities and discuss how countries could cooperate in the area of dossier assessment and GMP inspection.
![Page 4: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/4.jpg)
2006.08.21. Pogány - Tanzania 4/36
Subjects for discussion1. Interchangeability of multisource (generic)
FPPs2. EoI for Antimalarial Drugs3. Global quality issues4. Prequalification Experience – Illustrative
deficiencies5. Pharmaceutical Quality Information Form6. Main points again
![Page 5: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/5.jpg)
2006.08.21. Pogány - Tanzania 5/36
Interchangeability (IC)Interchangeability (IC) of multisource FPPs =
(Essential similarity with innovator FPP) =
Pharmaceutical equivalence (PE) +
Bioequivalence (BE)
IC = PE + BE
![Page 6: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/6.jpg)
2006.08.21. Pogány - Tanzania 6/36
INACTIVE INGREDIENT
S
ACTIVE INGREDIENT
S
PACKING MATERIALS
FPP Manufacturing process
Manufacturing
authorization
Marketingauthorization
GMP standards
Pharmacopeiastandards
NATIONAL DRA1
NATIONAL DRA2
CRITICAL VARIABLES OF FPP QUALITY
![Page 7: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/7.jpg)
2006.08.21. Pogány - Tanzania 7/36
Pharmaceutical equivalence FPPs meet same or comparable standards
(pharmacopoeia, marketing authorization) Same API (chemical and physical equivalence) Same dosage form and route of administration Same strength Dissolution profile equivalence, when applicable Comparable labeling
WHO-GMP (batch-to-batch uniformity of quality)
Stability equivalence
![Page 8: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/8.jpg)
2006.08.21. Pogány - Tanzania 8/36
High quality-risk APIs FPP is not registered in the ICH region and associated
countries API is not official in the internationally used major
pharmacopoeias and ICH guidelines should be used for evaluation
Reference standard/comparator is not available for: Pharmaceutical equivalence studies Bioequivalence studies
Require particular attention by NDRA as regards assessment of applications for marketing authorization
![Page 9: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/9.jpg)
2006.08.21. Pogány - Tanzania 9/36
Low quality-risk APIs1. Certificate of suitability (CEP) is submitted (DRA)2. Drug Master File
Open part (APPLICANT) Closed part (DRA)
3. Pharmacopeia monograph is available Literature evidence of stability Synthesis impurities and degradants are controlled by
monograph Class1 solvents excluded; class2 / class 3 solvents controlled
4. FPP is registered in the ICH region (DRA)
![Page 10: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/10.jpg)
EXPRESSION of INTEREST (4th edition, May 2005)
Artemisinin-based Antimalarial FPPs
![Page 11: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/11.jpg)
2006.08.21. Pogány - Tanzania 11/36
EoI – Oral Preparations Artesunate* + Amodiaquine Artemether* + Lumefantrine* Artesunate* + Mefloquine Artesunate* + SP (sulphadoxine / pyrimethamine)
* Assessed originally by ICH guidelines * High quality-risk API
+ ... FDC or co-blistered (co-packaged) FPPsAll oral FPPs include paediatric formulations.(EOI is included in the Notes Page of this and the subsequent slides)
![Page 12: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/12.jpg)
2006.08.21. Pogány - Tanzania 12/36
EoI – Other dosage forms Artemether Injection and rectal FPPs Artemotil (arteether) Injection Artesunate Injection and rectal FPPs Only FPPs listed in the EOI are assessed.
![Page 13: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/13.jpg)
2006.08.21. Pogány - Tanzania 13/36
History and Current Status First EOI published on 8 May 2002 Assessment of dossiers started in July
2002 FPPs [51 applications (2 cancelled) - five
(three FPPs) approvals as at 1 July 2006]. Antimalarial FPPs –manufactured in Africa – have not yet been prequalified.
Problems delaying prequalification are discussed in forthcoming slides
![Page 14: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/14.jpg)
GLOBAL QUALITY ISSUES
ANTIMALARIAL FPPs
![Page 15: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/15.jpg)
2006.08.21. Pogány - Tanzania 15/36
Global regulatory issues If the product has been locally developed and
manufactured, the national DRA must evaluate the data set itself (p. 23)1.
If an evaluation report —critical summary and interpretation of the data, with conclusions— is not available it is not possible to seek a WHO-type certificate (p. 23)1.
![Page 16: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/16.jpg)
2006.08.21. Pogány - Tanzania 16/36
Global regulatory issuesAPI or FPP originate „legally” from countries where:
Manufacture of APIs is not regulated Pharmaceutical exports and imports are
not regulated MA of FPPs is issued without evaluation
or with a check-list assessment by the national NDRA
![Page 17: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/17.jpg)
2006.08.21. Pogány - Tanzania 17/36
Global regulatory issues Formal stability studies are not required for
MA Biostudies are not required for MA National Good Manufacturing Practices
(GMP) do not comply with WHO-GMP requirements
API was not official in internationally used major pharmacopoeias (artemisinines and ARVs)
![Page 18: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/18.jpg)
2006.08.21. Pogány - Tanzania 18/36
Artemisin-derivative issues No innovator FPP is registered in the ICH region. No
comparator was available for: Pharmaceutical equivalence studies Bioequivalence studies
The APIs and FPPs were not official in the internationally used major pharmacopoeias
WHO guides/SOPs apply to multisource FPPs. ICH guides had to be used.
![Page 19: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/19.jpg)
PREQUALIFICATION EXPERIENCE
ILLUSTRATIVE EXAMPLES OF DEFICIENCIES
![Page 20: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/20.jpg)
2006.08.21. Pogány - Tanzania 20/36
Chemical synthesis Detailed information on the synthesis of non-
compendial APIs —or a flow chart and textbook-level narrative on official APIs— was not provided.
The final purification, crystallization and subsequent operations were not described in details.
Existence/absence of polymorphs, hydrates/solvates, solubility in water and organic solvents at 25oC, pKa, hygroscopicity data were not submitted.
![Page 21: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/21.jpg)
2006.08.21. Pogány - Tanzania 21/36
Stability testing Stress stability (forced degradation) testing
was limited to analytical method validation studies and were conducted under harsh conditions to produce degradants that may not be observed under the accelerated stress studies .
“Room temperature and accelerated stability tests are in progress.”
![Page 22: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/22.jpg)
2006.08.21. Pogány - Tanzania 22/36
Specifications of API The melting point is 143-145oC (p.4) as
opposed to 131-134oC ± 1.5oC in the DMF. Individual impurity limits were not based on
batch analysis results and they were not in line with the ICH guidelines (e.g., NMT 1.0% instead of NMT 0.1%).
Residual solvents were included in the in-house monograph but not in the DMF.
![Page 23: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/23.jpg)
2006.08.21. Pogány - Tanzania 23/36
Specifications of API No adequate information was provided on the
preparation and quality specification of primary (absolute) and secondary (working) standards. (For instance, lack of complete CoA, assay by two different validated methods, detailed information on storage, etc.).
HPLC method is described as an alternative assay to titration but acceptance limits are 97-103% as opposed to 98-102% in the DMF.
![Page 24: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/24.jpg)
2006.08.21. Pogány - Tanzania 24/36
Development pharmaceutics A report was not submitted to identify and
describe the formulation and process attributes that can influence batch reproducibility, product performance and FPP quality, including stability.
A tabulated summary of the compositions of the FPP used in clinical trials or stability studies and a presentation of dissolution profiles was not provided.. Dissolution time was not studied at all.
![Page 25: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/25.jpg)
2006.08.21. Pogány - Tanzania 25/36
Stability of FPP and SmPC Degradants, dissolution rate and profile,
water content, hardness, microbiological attributes, etc. were not tested or quantified.
A national DRA-approved Summary of Product Characteristics (SmPC) type information for health professionals was not submitted.
![Page 26: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/26.jpg)
2006.08.21. Pogány - Tanzania 26/36
Correspondence with manufacturers The stress data show that the blister pack
does not protect the tablets even if overwrapped by additional protective packing. Supplier reduced expiry date.
Analysis of the tests for microbiological purity on „two (2) batches showed contamination with an invading yeast.”
![Page 27: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/27.jpg)
PREQUALIFICATION QUALITY
REQUIREMENTSSTANDARDS, GUIDELINES
and TEMPLATES
![Page 28: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/28.jpg)
2006.08.21. Pogány - Tanzania 28/36
International Pharmacopoeia Artemether Artemisinin Artemotil Artenimol Artesunate Mefloquine Hydrochloride Proguanil Hydrochloride BP
![Page 29: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/29.jpg)
2006.08.21. Pogány - Tanzania 29/36
International quality standards Amodiaquine USP Amodiaquine Hydrochloride USP Lumefantrine Pyrimethamine BP, PhEur, PhInt, USP Sulphadoxine BP, PhEur, PhInt, USP
![Page 30: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/30.jpg)
2006.08.21. Pogány - Tanzania 30/36
Prequalification quality guidelines1. Guide on Submission of Documentation for
Prequalification of innovator Finished Pharmaceutical Products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis and approved by Drug Regulatory Authorities (DRAs) in the International Conference on Harmonization (ICH) region and associated countries, including among others the EU, Japan and USA
![Page 31: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/31.jpg)
2006.08.21. Pogány - Tanzania 31/36
Prequalification quality guidelines2. Guideline on Submission of Documentation
for Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDS, Malaria and Tuberculosis, together with eight (8) annexes.
3. Guidance on Variations to a Prequalified Dossier
![Page 32: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/32.jpg)
2006.08.21. Pogány - Tanzania 32/36
Prequalification quality guidelines4. Supplement 1 [for use from July 2005
(CPH25)] - Dissolution testing5. Supplement 2 – Revision 1[for use from
May 2006 (CPH31)] - Extension of the WHO List of Stable (not easily degradable ARV) APIs1
1World Health Organization, WHO Technical Report Series, No. 863, 1996. Annex 5 Guidelines for stability testing of pharmaceutical products containing well-established drug substances in conventional dosage forms.
![Page 33: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/33.jpg)
2006.08.21. Pogány - Tanzania 33/36
Annex 8 to the Generic GuidelinePharmaceutical Quality Information Form The PQIF contains summary information provided by the applicant on critical pharmaceutical quality attributes –chemistry, pharmaceutical formulation, manufacturing process and product performance– and their relevance to safety and efficacy, following the structure of the Generic Guideline and frequently in tabulated forms. Focus on analytical and stability issues, development pharmaceutics and specifications.
![Page 34: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/34.jpg)
2006.08.21. Pogány - Tanzania 34/36
Main points again1. WHO provides information to African regulators
and pharmaceutical manufacturers about the ongoing activities of the PQ program and discuss how countries could further benefit from cooperation in the area of dossier assessment and GMP inspection.
2. The EoI limits the number of FPPs.3. Many DRAs did not assess generic FPPs –used in
the treatment of HIV/AIDS, malaria and tuberculosis– and most manufacurers did not have dossiers for MA, at the beginning of PQ.
![Page 35: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/35.jpg)
2006.08.21. Pogány - Tanzania 35/36
Main points again4. Artemisinin-derived APIs and FPPs were marketed at
global level for decades without meeting basic standards of quality.
5. It takes time to get into prequalification compliance Develop new formulation Data to be generated, tests carried out GMP upgrade needed
6. Increase in the number of prequalified Artesunate Tablets is expected because there has been an official comparator since 2005.
![Page 36: WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence](https://reader033.vdocuments.site/reader033/viewer/2022061423/56815dee550346895dcc1a1c/html5/thumbnails/36.jpg)
2006.08.21. Pogány - Tanzania 36/36
PLEASE MAKE USE OF THE OPPORTUNITY
TO PARTICIPATE IN THE PREQUALIFICATION
PROJECT